MODALIS THERAPEUTICS CORPORATION |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 71 JPY | -5.33% |
|
-10.13% | -42.74% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
| Sales 2022 | 40M 257K | Sales 2023 | - | Capitalization | 3.92B 25.13M |
|---|---|---|---|---|---|
| Net income 2022 | -2.7B -17.34M | Net income 2023 | -2.39B -15.35M | EV / Sales 2022 | 171 x |
| Net cash position 2022 | 2.93B 18.82M | Net cash position 2023 | 1.47B 9.44M | EV / Sales 2023 | - |
| P/E ratio 2022 |
-3.61
x | P/E ratio 2023 |
-1.61
x | Employees | 37 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 83.39% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -5.33% | ||
| 1 week | -10.13% | ||
| Current month | -7.79% | ||
| 1 month | -22.83% | ||
| 3 months | -28.28% | ||
| 6 months | -44.09% | ||
| Current year | -42.74% |
1 week
69.00
81.00
1 month
69.00114.00
Current year
69.00126.00
1 year
69.00336.00
3 years
69.001 849.00
5 years
69.004 070.00
10 years
69.004 070.00
| Managers | Title | Age | Since |
|---|---|---|---|
Haru Morita
FOU | Founder | 54 | 15-12-31 |
Naoki Kobayashi
DFI | Director of Finance/CFO | 60 | - |
Tetsuya Yamagata
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Joseph McCracken
BRD | Director/Board Member | 71 | 18-07-31 |
Toshio Furuta
BRD | Director/Board Member | 62 | 18-11-30 |
Haru Morita
FOU | Founder | 54 | 15-12-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-10 | 71 | -5.33% | 915,000 |
| 24-05-09 | 75 | -3.85% | 1,186,400 |
| 24-05-08 | 78 | -2.50% | 401,500 |
| 24-05-07 | 80 | +1.27% | 92,300 |
Delayed Quote Japan Exchange, May 10, 2024 at 02:00 am EDT
More quotes
Modalis Therapeutics Corp is a Japan-based company engaged in the research and development of gene therapy drugs using the core platform CRISPR-GNDM technology. The Company develops gene therapy drugs that use CRISPR-GNDM technology, which is a unique platform technology, for genetic diseases caused by errors in the genetic code and epigenetics. The Company has two business models. Collaborative model pipeline opens CRISPR-GNDM technology to partners, and develops therapeutic drugs with partners' funds for the targets selected by the partners. In-house model pipeline selects targets using the Company's own CRISPR-GNDM technology and develops therapeutic agents. The Company's pipeline consists of a collaborative model pipeline of 5 items such as MDL-201 and an in-house model pipeline of 2 items such as MDL-101.
Calendar
2024-08-01
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -42.74% | 15.57M | |
| +3.91% | 109B | |
| +10.87% | 105B | |
| +1.28% | 22.25B | |
| -13.14% | 22.09B | |
| -7.05% | 18.68B | |
| -38.36% | 17.58B | |
| -10.66% | 16.85B | |
| +3.75% | 13.76B | |
| +36.70% | 12.46B |
- Stock Market
- Equities
- 4883 Stock